TERN Terns Pharmaceuticals, Inc.
USHealthcareAs of 2026-05-15 16:00
Why TERN matters now
Terns Pharmaceuticals, Inc. (TERN) is a US stock in Healthcare. The latest InvestLog snapshot shows $52.95 with -0.03% on the session and $4.77B in market capitalization; recent performance reads 1-month +0.00% and YTD +31.06%.
The latest financial table shown here is Q4 2025, with revenue of $0.00, net income of $-23.6M, and EPS of $-0.24. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.7%.
The latest indexable market news headline is "Tern shares surge as it ups stakes in AI health services company Talking Medicines" from Proactive Investors.
Additional event context on this page matters because analyst consensus is Hold with a median target of $55.50; recent insider activity includes Burroughs Amy L. filing D-Return. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.90
P/S
0.00
EV/EBITDA
-40.01
DCF Value
$5.60
FCF Yield
-1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-20.0%
ROA
-9.4%
ROIC
-10.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-23.6M | $-0.24 |
| FY 2025 | $0.00 | $-96.2M | $-1.03 |
| Q3 2025 | $0.00 | $-24.6M | $-0.27 |
| Q2 2025 | $0.00 | $-24.1M | $-0.26 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$55.50
Target (Median)
$55.50
Target Range
$53.00 - $58.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.38
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.